#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Incretins have changed and continue to change treatment strategy for type 2 diabetes


Authors: M. Kvapil
Authors‘ workplace: Interní klinika 2. lékařské fakulty UK a FN Motol Praha, přednosta prof. MUDr. Milan Kvapil, CSc., MBA
Published in: Vnitř Lék 2011; 57(11): 916-918
Category: Birthday

Overview

Incretins are a novel class of drugs indicated for therapeutic intervention in patients with type 2 diabetes. They provide effective and safe therapy. Their advantages include low risk of hypoglycaemia and positive effect on body weight. Literature published so far consistently evidences reduced cardiovascular risk. If long-term prospective studies confirm such an effect, incretin therapy will, together with metformin, become the first line treatment for type 2 diabetes.

Key words:
type 2 diabetes mellitus – gliptins – GLP-1 receptor agonists – cardiovascular risk


Sources

1. Anagnostis P, Athyros VG, Adamidou F et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011; 13: 302–312.

2. Ahrén B. Gut peptides and Type 2 diabetes mellitus treatment. Curr Diab Rep 2003; 3: 365–372.

3. Amori RE, Lau J, Pittas AG. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis. JAMA 2007; 298: 194–206.

4. Best JH, Hoogwerf BJ, Herman WH et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011; 34: 90–95.

5. Buse JB, Rosenstock J, Sesti G et al. LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39–47.

6. D’Alessio DA, Vahl TP. Glucagon-like peptid 1: evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab 2004; 286: E882–E890.

7. Davidson MH. Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol 2011; 108 (3 Suppl): 33B–41B.

8. Demuth HU, McIntosh CH, Pederson RA. Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 2005; 1751: 33–44.

9. Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010; 70: 489–512.

10. Drucker DJ, Buse JB, Tailor K et al. DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240–1250.

11. Karasik A, Aschner P, Katzeff H et al. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 2008; 24: 489–496.

12. Gilbert MP, Pratley RE. Efficacy and Safety of incretin-based therapies in patients with type 2 diabetes mellitus. Am J Med 2009; 122; S11–S24.

13. Richter B, Bandeira-Echtler E, Bergerhoff K et al. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008; 4: 753–768.

14. Fakhoury WK, Lereun C, Wright D. A Meta-Analysis of Placebo-Controlled clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Pa­tients with Type 2 Diabetes. Pharmacology 2010; 86: 44–57.

15. Waugh N, Cummins E, Royle P et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010; 14: 1–248.

16. Williams-Herman D, Engel SS, Round E et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010; 10: 7.

17. Sullivan SD, Alfonso-Cristancho R, Conner C et al. A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. Pharmacotherapy 2009; 29: 1280–1288.

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 11

2011 Issue 11

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#